Vertex signs LOI for ALYFTREK in Canada
Analysis based on 6 articles · First reported Jul 06, 2026 · Last updated Jul 06, 2026
The LOI is a positive step for Vertex's Canadian market access for ALYFTREK, potentially expanding its patient base and revenue. However, the stock was down 1.14% on the day, suggesting limited immediate market reaction.
Vertex Pharmaceuticals announced on July 6, 2026 that it has signed a Letter of Intent (LOI) with the Pan-Canadian Pharmaceutical Alliance (pCPA) for ALYFTREK (vanzacaftor/tezacaftor/deutivacaftor), a triple combination therapy for cystic fibrosis (CF) in patients aged 6 and older with at least one F508del mutation. The LOI follows positive reimbursement recommendations from Canada — Canada s Drug Agency (CDA-AMC) in December 2025 and Institut national d'excellence en sante et en services sociaux (INESSS) in April 2026. Approximately 3,800 people in Canada are now eligible for ALYFTREK, with up to 60 individuals potentially receiving treatment for the underlying cause of their disease for the first time. Vertex will now initiate discussions with provinces and territories to support public listing of ALYFTREK through publicly funded drug programs. ALYFTREK is already approved in the United States, United Kingdom, European Union, Canada, New Zealand, Switzerland, and Australia.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard